NSE: BLUEJET · BSE: 544009 · ISIN INE0KBH01020
Blue Jet Healthcare Limited stock analysis
Blue Jet Healthcare Limited ranks #407 in the TickerSutra evidence-ranked universe with a score of 65/100 and 89% data confidence. The latest captured fundamentals show ROCE of 26.1%, quarterly sales growth of -17.4% and quarterly profit growth of -14.2%.Watchlist candidate
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- ROCE is 26.1%
- Low debt/equity of 0.03×
- Strong CFO/EBITDA of 1.14×
- Institutional ownership is rising
- CWIP indicates an active capacity pipeline
- No promoter shares are reported as pledged
Risks and constraints
- Operating margin has compressed materially
- Valuation is above 40× earnings
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹683cr | ₹249cr | ₹182cr | 36.0% |
| 2023 | ₹721cr | ₹219cr | ₹160cr | 30.0% |
| 2024 | ₹712cr | ₹231cr | ₹164cr | 32.0% |
| 2025 | ₹1,030cr | ₹378cr | ₹305cr | 37.0% |
| 2026 | ₹947cr | ₹294cr | ₹248cr | 31.0% |
| TTM | ₹886cr | ₹271cr | ₹235cr | 31.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
Scrutinizer''s Report and voting results for AGM
RoutineShareholders meetingNSE · 23 Sept 2026Blue Jet Healthcare Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on September 21, 2026. Further, the company has informed the Exchange regarding voting results.
RoutineBlue Jet Healthcare Ltd - 544009 - Shareholder Meeting / Postal Ballot-Outcome of AGMBSE · 21 Sept 2026Outcome of 58th Annual General Meeting of the Company
RoutineShareholders meetingNSE · 21 Sept 2026Blue Jet Healthcare Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 21, 2026
MANAGEMENT COMMENTARY
Signals from filed documents
Our investment in the Vizag greenfield facility marks a massive expansion thrust, reinforcing our CDMO scale while boosting capacity for high-value chemical and pharmaceutical ingredients. We are also on track with the backward integration at the Mahad facility, which will enable supply chain fortification and capacity enhancement at the manufacturing site. The project will strengthen efficiency and scale while promo
FY 2026-27 AND BEYOND We enter FY 2026-27 with improving order visibility across all three segments, a strengthened manufacturing and R&D footprint, and a clean balance sheet augmented by the Board-approved fundraise of up to ₹1,000 crores. Further the Company has raised ₹800 crores through Qualified Institutional Placement. The structural opportunity — global CDMO outsourcing, India's growing role in pharmaceutical
Aligned with the external environment, Revenue from Operations declined by 8% to ₹9,473 million, while Profit After Tax (PAT) stood at ₹2,478 million, down 18.8% over the previous year. This was driven by a reduction in the PI & API segment, owing to customer inventory destocking and pricing pressure in the artificial sweeteners business. Despite the annual revenue dip and compressed margins, the Company remained hig
Key trends include: • Policy pushes for self-reliance through PLI schemes and large investments • Focus on complex APIs, biologics, and specialty products • Expansion of bulk drug parks and manufacturing capacity • Growing global demand for diversified sourcing beyond China • Increased emphasis on sustainability and compliance • Rising outsourcing partnerships with global pharma and CDMOs Despite near-term challenges
STRATEGIC EXPANSION & GROWTH Aligned with the transforming demand contours and market evolution, we continue to expand our manufacturing capabilities and capacities through targeted investments. Our investment in the Vizag greenfield facility marks a massive expansion thrust, reinforcing our CDMO scale while boosting capacity for high-value chemical and pharmaceutical ingredients. We are also on track with the backwa
This reduction is partially through raw material price increase and due to product mix. Being in the CDMO business, our customers are resilient enough for a pass-through of raw material cost variance with a few quarter gap. Our operating EBITDA at 33.5% is an increase of 3% over previous quarter.
Growth is driven by rising healthcare demand, chronic disease burden, and strong export momentum across regulated and emerging markets. Key trends include: • Policy pushes for self-reliance through PLI schemes and large investments • Focus on complex APIs, biologics, and specialty products • Expansion of bulk drug parks and manufacturing capacity • Growing global demand for diversified sourcing beyond China • Increas
Our operating EBITDA at 33.5% is an increase of 3% over previous quarter. This expansion of gross EBITDA margin is on account of operating leverage on a higher sale. Profit after tax at 26.17% is lower by 0.7% than the previo us quarter.
of times) FY24 FY25 FY26 4.77 3.97 3.75 PAT (₹ in million) FY24 FY25 FY26 1,638 3,052 2,478 PAT MARGIN (%) FY24 FY25 FY26 23.01 29.63 26.16 ROCE (%) FY24 FY25 FY26 26.01 35.85 24.91 15 MANUFACTURING EXCELLENCE Fuelling Capacity-Led Growth to DRIVE PROGRESS Focussed on precision, agility, and consistent delivery across complex chemistry segments, our facilities integrate modular infrastructure and semi-automated proce
• The Board and management provide oversight on governance matters, ensuring accountability, transparency, and alignment with stakeholder interests. • The Company actively engages with regulators and relevant stakeholders to ensure ongoing compliance and adherence to evolving regulatory requirements. Negative: Increased compliance and legal costs, regulatory penalties, loss of business opportunities, restricted marke
Additionally, the rapid expansion of the processed food and beverage sector, supported by government initiatives such as the Production Linked Incentive Scheme, is significantly boosting sweetener consumption. A key industry trend is the shift toward high-intensity sweeteners, which are expected to grow faster than traditional bulk sweeteners due to regulatory approvals and reformulation efforts by manufacturers. Sim
The shift from small molecules STATUTORY REPORTS 49 toward biopharmaceuticals such as monoclonal antibodies and mRNA therapies is reshaping service requirements and driving innovation in manufacturing technologies. Strategic trends include integrated end-to-end service offerings, mergers and acquisitions, and geographic expansion, particularly in Asia-Pacific, which remains the largest regional market. However, chall
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…